BIO Stalwart Greenwood Announces Departure
Executive Summary
Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.
You may also be interested in...
BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins – BIO’s Greenwood
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.